We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Evaluation of Neurocognitive Performance in Drug Substituted Patients Under Hepatitis C Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00682591
Recruitment Status : Withdrawn (Study had to be withdrawn because financial support was cancelled.)
First Posted : May 22, 2008
Last Update Posted : February 4, 2009
Information provided by:

May 20, 2008
May 22, 2008
February 4, 2009
July 2008
December 2011   (Final data collection date for primary outcome measure)
Time course of neurocognitive performance (as assessed by the TAP - Test Battery for Attentional Performance) [ Time Frame: Repeated measures design with the following evaluation timepoints: baseline, twice to four times during antiviral treatment, twice after antiviral treatment ]
Same as current
Complete list of historical versions of study NCT00682591 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Evaluation of Neurocognitive Performance in Drug Substituted Patients Under Hepatitis C Therapy
Evaluation of Neurocognitive Performance, Quality of Life, and Emotional State in Drug Substituted Patients (Methadone, Buprenorphine, Suboxone) Under Hepatitis C Therapy (Peginterferon Alfa and Ribavirin)

Prospective, longitudinal multi-center study performed in 15 participating substitution centers in Germany.


- Primary objective: To compare the impact of the different substitution drugs (methadone, buprenorphine, and suboxone) on the neurocognitive, emotional, and quality-of-life-related tolerability in opioid dependent patients under HCV treatment.

- Secondary objective: To investigate if IFN therapy impairs efficacy (with respect to e.g. retention rates, concomitant drug use and in particular neurocognitive function) and tolerability of agonist maintenance treatment with methadone, buprenorphine, or suboxone

Not Provided
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Outpatients with chronic hepatitis C infection and drug substitution therapy (methadone, burpenorphine, suboxone)
Chronic Hepatitis C Infection
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2011
December 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Opioid-dependent patients on current stable agonist maintenance therapy (for at least 6 months prior to study enrolment) with methadone, buprenorphine, or suboxone.
  • Patients need to be infected with chronic hepatitis C and must have indication for therapy with peginterferon alfa and ribavirin.
  • Patients with informed written consent with respect to a follow-up of psychiatric side effects and in particular neurocognitive performance.
  • Patients with baseline monitoring of emotional state and neurocognitive performance.

Exclusion Criteria:

  • According to SPC
  • According to legal requirements reg. drug substitution therapy (BTMVV)
  • Insufficient knowledge of the German language or cognitive impairment (due to the indispensable application of questionnaires and the TAP, Test Battery of Attentional Performance).
  • Age under 18 years or over 65 years
  • coinfections such as hepatitis B virus or human immunodeficiency virus
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Michael Scheurlen, MD (principal investigator), University of Wuerzburg, Germany
University of Wuerzburg
Not Provided
Principal Investigator: Michael Scheurlen, MD Med. Klinik und Poliklinik II, University of Wuerzburg
University of Wuerzburg
February 2009